GoodRx Holdings, Inc. (GDRX)

SEC filings indicate GoodRx has stabilized revenue and returned to profitability, supported by strong operating cash flow and manageable leverage. Valuation looks more reasonable on enterprise-value-to-EBITDA and free-cash-flow yield than on headline P/E, but recent quarters show softer revenue and lower GAAP earnings versus the prior year, keeping conviction moderate. Key disclosed risks include reliance on a limited set of industry participants and pricing structures, plus litigation exposure (including TCPA-related claims).

GoodRx's near-term tape is mildly constructive and improving: the dominant in-window catalyst is the preliminary court approval of the $32M consumer data-sharing settlement (announced, 2026-09-09, scored +0.20) alongside the Companion Family Plan launch (2026-09-03), while the news sentiment delta is determinate-positive but thin (+0.067 baseline vs +0.20 scoring, scoring side n=1) and retail chatter is silent. A moderate red-flag cap applies (confirmed material litigation — Doe v. GoodRx, N.D. Cal, final settlement approval pending), leaving a mixed, forming setup.

Score 3 (mixed): constructive longer-term structure — price 3.38 holds above the SMA50 (3.37) and well above the SMA200 (2.72) with support at the 3.31–3.33 zone — but the short-term read is soft: price sits below the SMA20 (3.46), EMA9 (3.43), EMA21 (3.45), WMA9 (3.42), WMA21 (3.45) and DEMA14 (3.42) after a failed 09-14 breakout to 3.58 and three straight down days; MACD rolled over at the zero line (line 0.00 vs signal 0.02, histogram -0.02), RSI 46.95 is neutral, Williams %R -67.74 mildly weak, and ADX 22.33 shows no directional trend strength. The trade is blocked by the 20-day liquidity floor: avgDollarVolume20 is $4,239,912, below the $5,000,000 minimum, so no plan can be built despite the chart holding above its intermediate uptrend.